Lexaria Bioscience Corp (LEXX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.35M
Last updated: Nov 17, 2026 at 4:10 PM ET
Lexaria Bioscience Corp (LEXX) Stock Chart
Lexaria Bioscience (LEXX) has a latest price of $4.18 on Nov 17, 2026, 80.6% below its 52-week high of $21.60. Its price fell 73.7% over the past 12 months. The month-end price fell 97.5% since Dec 2016, a compound annual decline of 31.3%.
Price Chart
From Dec 2016 to Oct 2026, its highest month-end close was $922.96 in Aug 2018 and its lowest $3.15 in Sep 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart LEXX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for LEXX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 63.7%, and over 6 months it fell 51.7%. The month-end price fell 83.1% over the 3 years through Oct 2026, a compound annual decline of 44.7%.
| Period | Change |
|---|---|
| 1 month | +60.8% |
| 3 months | -63.7% |
| 6 months | -51.7% |
| 12 months | -73.7% |
| 12 months, with dividends | -73.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -83.1% | -44.7% |
| 5 years | -96.2% | -48.1% |
| Since Dec 2016 | -97.5% | -31.3% |
Price by Year
Its best calendar year was 2017, when the price rose 445.2%, and its weakest was 2025, when it fell 70.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.49 | -62.3% |
| 2025 | $9.25 | -70.6% |
| 2024 | $31.48 | +68.0% |
| 2023 | $18.74 | -49.2% |
| 2022 | $36.88 | -39.0% |
| 2021 | $60.42 | -46.2% |
| 2020 | $112.24 | -34.4% |
| 2019 | $171.09 | -59.1% |
| 2018 | $418.71 | -45.0% |
| 2017 | $760.88 | +445.2% |
Trading Range
The price is 18.7% above its 50-day average of $3.52 and 50.9% below its 200-day average of $8.51.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $4.18 | |
| 52-week high | $21.60 | -80.6% |
| 52-week low | $2.43 | +72.0% |
| 50-day average | $3.52 | +18.7% |
| 200-day average | $8.51 | -50.9% |
Price Risk
Over 3 years, its largest fall from a peak was 97.2%.
| Measure | Value |
|---|---|
| 1-year beta | 0.80 |
| Largest fall, 1 year | -87.1% |
| Largest fall, 3 years | -97.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About LEXX
What is LEXX's 1-year price change?
Lexaria Bioscience's price fell 73.7% over the past 12 months. With dividends included, the 12-month total return was -73.7%.
What is LEXX's 5-year price change?
Lexaria Bioscience's month-end price fell 96.2% over the 5 years through Oct 2026, a compound annual decline of 48.1%. These figures leave out dividends.
What is LEXX's 52-week high and low?
Lexaria Bioscience's 52-week high is $21.60 and its 52-week low is $2.43. Its latest price of $4.18 on Nov 17, 2026 is 80.6% below the high.
What is LEXX's beta?
Lexaria Bioscience's 1-year beta against the S&P 500 is 0.80, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 87.1%.
Is the LEXX chart free?
Yes. Advanced Charting for LEXX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
LEXX pages: Overview, Charting, Earnings, Financials, Statistics